Andreas Struengmann & family

$11.12B
$244.7M (2.3%)
as of 05/20/25

About Andreas Struengmann & family

Andreas Struengmann and twin brother Thomas were early backers of BioNTech, which partnered with Pfizer to make a vaccine for Covid-19.

The brothers cofounded generic drugmaker Hexal in 1986 and sold it to Novartis in 2005 for some $7 billion.

The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.

In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.

Personal stats

Citizenship

Germany

Source of wealth

Pharmaceuticals

Residence

Tegernsee, Germany

Marital status

Married

Birth date

02/16/50 (age 75)

Number of children

2

Education

Medical Doctor, University at Buffalo

Self-made

self-made

Andreas Struengmann & family’s fortune is worth

185K

troy ounces of gold

171K

median U.S. household

111K

median U.S. income

0.222%

U.S. credit card volume

0.044%

GDP of the United States

0.033%

United States debt

Net worth history

Annual ranking

Did you know?

After studying medicine in Freiburg, Germany, Andreas worked as a doctor in South Africa.

Net worth over time

Real-time ranking

Financial assets

NASDAQ | BNTX-US

BioNTech Sponsored ADR

undefined | undefined

Formycon

Images © Forbes.com. All rights reserved.